• Turning Point Brands reaffirmed full-year 2026 Modern Oral gross sales guidance of $330 million-$350 million.
• Net sales outlook held at $260 million-$270 million.
• EBITDA guidance narrowed to $70 million-$80 million from $70 million-$90 million.
• Assumes no margin benefit from onshoring manufacturing until 2027.
• Forecast reflects expectations for prolonged, higher freight costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turning Point Brands Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609210900BIZWIRE_USPR_____20260921_BW237929) on September 21, 2026, and is solely responsible for the information contained therein.